Rare Disease News and Research

RSS

Imbruvica gets FDA approval for treatment of mantle cell lymphoma

The U.S. Food and Drug Administration today approved Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma, a rare and aggressive type of blood cancer.

13 Nov 2013

Promethera Biosciences completes patient enrolment for first clinical trial of HepaStem

Promethera Biosciences, a Belgian biotechnology company developing Promethera HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, announces today the completion of patient enrolment for its first clinical trial.

12 Nov 2013

Research findings may lead to new treatments, approaches for controlling multiple sclerosis

Scientists are gaining a new level of understanding of multiple sclerosis that may lead to new treatments and approaches to controlling the chronic disease, according to new research released today at Neuroscience 2013, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news about brain science and health.

10 Nov 2013

Musicians can develop saxophone lung from fungus

Reed instruments, such as the clarinet and saxophone, can be detrimental to your health if not properly cleaned. In a study presented at the American College of Allergy, Asthma and Immunology's Annual Scientific Meeting in Baltimore, Nov. 7-11, researchers noted that musicians can develop allergic pulmonary disease to specific funguses that collect over time in the instrument's reed.

8 Nov 2013

Patrys receives FDA Orphan Medicinal Product Designation for PAT-SM6

Patrys Limited, a clinical stage biotechnology company, has received confirmation of Orphan Medicinal Product Designation for its lead anti-cancer product PAT-SM6, from the USA Food and Drugs Administration.

7 Nov 2013

FDA grants Orphan Drug Designation to Advaxis' ADXS-HPV for HPV-associated head and neck cancer

Advaxis, Inc.,, a leader in developing the next generation of cancer immunotherapies, announced that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration Office of Orphan Products Development for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus-associated head and neck cancer.

6 Nov 2013

Trophos completes efficacy study of olesoxime in patients with Spinal Muscular Atrophy

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, has completed its efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy.

5 Nov 2013

Viropharma announces financial results for third quarter 2013

ViroPharma Incorporated reported today its financial results for the third quarter ended September 30, 2013. Net sales were $113 million for the third quarter ended September 30, 2013, as compared to $91 million in the same three months of 2012.

31 Oct 2013

Two related genes underlie development of two rare bone tumours in nearly 100% of patients

Scientists have made a rare discovery that allows them to attribute two types of tumour almost entirely to specific mutations that lie in two related genes.

28 Oct 2013

Complete Care program improves outcomes for Kaiser Permanente patients

Complete Care, a collaborative approach to meeting patient needs, is improving outcomes for Kaiser Permanente patients.

23 Oct 2013

Illumina announces launch of TruGenome Undiagnosed Disease Test

Illumina, Inc. today announced the launch of its TruGenome Undiagnosed Disease Test provided by the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.

From Illumina, Inc. 22 Oct 2013

New collaborative project aims to discover genes underlying rare genetic diseases

...

21 Oct 2013

Thomson Reuters adds Cortellis Clinical Trials Intelligence for drug discovery and development

The Intellectual Property & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, today announced the addition of Clinical Trials Intelligence to the Thomson Reuters CortellisTM suite, the industry's most comprehensive information solution for drug discovery and development.

19 Oct 2013

Researchers identify novel gene mutation that causes common variable immunodeficiency

A 30-year-old woman with a history of upper respiratory infections had no idea she carried an immunodeficiency disorder - until her 6-year-old son was diagnosed with the same illness.

18 Oct 2013

Researchers test ATR-101 compound in clinical trial for adrenal cancer

One of the most challenging cancers to treat is also one of the rarest, which only adds to the challenge of finding potential new therapies.

16 Oct 2013

Two institutions receive $25M grant from NIH to abet clinical and translational research

Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center have received a $25 million grant from the National Institutes of Health (NIH) for the Harold and Muriel Block Institute for Clinical and Translational Research (ICTR) at Einstein and Montefiore.

16 Oct 2013

Liposorber LA-15 System to treat pediatric patients with primary FSGS gets FDA approval

The U.S. Food and Drug Administration today approved Liposorber LA-15 System to treat pediatric patients with primary focal segmental glomerulosclerosis either before transplant, or after renal (kidney) transplantation in which there is recurrence of FSGS.

11 Oct 2013

Drugs often fail to bring acromegaly under control in routine clinical practice

Over a quarter of UK patients treated for growth hormone-producing tumours do not achieve 'safe' growth hormone levels, according to a 30 year UK multi-centre study of clinical management of the rare disease acromegaly. The findings by the Society for Endocrinology UK Acromegaly Register, published in the November issue of Clinical Endocrinology, show that drugs to control acromegaly often fail to bring the disease completely under control in routine clinical practice.

10 Oct 2013

Mechanism preserving genome integrity help develop new therapies against DiGeorge syndrome

An international team of scientists-including researchers at GENYO, the Centre for Genomics and Oncological Research (Pfizer-University of Granada- Andalusian Regional Government)-has described a molecular mechanism that facilitates the defence of the human genome against "bombarding" by mobile DNA sequences.